L A M Y (PK)【LMMY】銘柄情報

L A M Y (PK) (LMMY) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.4381

( - )

買値

0.18

売値

0.47

出来高

平均取引量 (3 か月)

US$ 1,720

財務取引量

0.00 日の範囲 0.00

0.0625 52 週間の範囲 0.94

時価総額

32.2M

企業価値

23M

前日終値

0.4381

始値

時刻

最終取引時間

VWAP

歳入

純利益

-80.16k

発行済株式数

73,500,000

浮動株比率 (%)

機関投資家保有比率 (%)

配当利回り

PER

-56.91

株価売上高倍率 (PSR)

1 株当たり利益 (EPS)

-0.01

ベータ

Exousia Bio, Inc., a biotechnology company, designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company’s platform enables the custom production of exosomes with enhanced gen... Exousia Bio, Inc., a biotechnology company, designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company’s platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases. The company was formerly known as LAMY and changed its name to Exousia Bio, Inc. in January 2026. The company was incorporated in 2022 and is based in Saint Petersburg, Florida. 詳細を表示

セクター

業界

ウェブサイト

exousiabio.com

本社

Saint Petersburg, United States

設立

2026

L A M Y (PK) is listed in the sector of the その他OTC with ticker LMMY. The last closing price for L A M Y (PK) was US$0.44. Over the last year, L A M Y (PK) shares have traded in a share price range of US$ 0.0625 to US$ 0.94.

L A M Y (PK) currently has 73,500,000 shares in issue. The market capitalisation of L A M Y (PK) is US$32.20 million. L A M Y (PK) has a price to earnings ratio (PE ratio) of -56.91.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview

Drawing on over 50 years of drug development experience, Dr. Hausman strengthens the Company’s mission to...

Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms

ORLANDO, FLORIDA / ACCESS Newswire / December 2, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced...

LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.

EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- LAMY...

Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value

ORLANDO, FLORIDA / ACCESS Newswire / November 17, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0.4381	0.4381	0.4381	500	0.4381	CS
12	0.0881	25.1714285714	0.35	0.47	0.315	1418	0.40608104	CS
26	0.0581	15.2894736842	0.38	0.5	0.26	1699	0.40074139	CS
52	0.0921	26.6184971098	0.346	0.94	0.0625	2876	0.40722134	CS
156	0.2381	119.05	0.2	16	0.06	10102	3.87305385	CS
260	0.2381	119.05	0.2	16	0.06	10102	3.87305385	CS